These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 7780018

  • 1. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
    Yu X, Ma Q.
    Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP.
    Vaccine; 2007 Dec 12; 25(51):8574-84. PubMed ID: 18045752
    [Abstract] [Full Text] [Related]

  • 4. A review of the current status of enteric vaccines.
    Levine MM, Noriega F.
    P N G Med J; 1995 Dec 12; 38(4):325-31. PubMed ID: 9522876
    [Abstract] [Full Text] [Related]

  • 5. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J, Mazumder R, Srivastava R, Srivastava BS.
    FEMS Immunol Med Microbiol; 2009 Jul 12; 56(2):179-84. PubMed ID: 19453752
    [Abstract] [Full Text] [Related]

  • 6. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J, Gibson JA, Pickering BS, Watnick PI.
    mSphere; 2018 Jun 27; 3(3):. PubMed ID: 29875145
    [Abstract] [Full Text] [Related]

  • 7. Oral vaccine against cholera prepared from Vibrio cholerae antigen(s).
    Chaicumpa W, Chaisri U, Tapchaisri P, Chongsa-Nguan M, Pongponratn E.
    Southeast Asian J Trop Med Public Health; 1987 Jun 27; 18(2):142-8. PubMed ID: 3313733
    [Abstract] [Full Text] [Related]

  • 8. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M, Karlsson SL, Källgård S, Blomquist M, Ekman A, Nygren E, Holmgren J.
    Vaccine; 2011 Oct 06; 29(43):7505-13. PubMed ID: 21807059
    [Abstract] [Full Text] [Related]

  • 9. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F.
    Vaccine; 2009 Feb 25; 27(9):1386-92. PubMed ID: 19146897
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ, Fürer E, Germanier R.
    Dev Biol Stand; 1983 Feb 25; 53():67-72. PubMed ID: 6873478
    [Abstract] [Full Text] [Related]

  • 11. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V, Sahoo SS, Das S, Ray S, Hardt WD, Suar M.
    Vaccine; 2015 Apr 08; 33(15):1880-9. PubMed ID: 25701672
    [Abstract] [Full Text] [Related]

  • 12. Stimulation of mucosal immune response following oral administration of enterotoxigenic Escherichia coli fimbriae (CFA/I) entrapped in liposomes in conjunction with inactivated whole-cell Vibrio cholerae vaccine.
    Dima VF, Ionescu MD, Palade R, Balotescu C, Becheanu G, Dima SV.
    Roum Arch Microbiol Immunol; 2001 Apr 08; 60(1):27-54. PubMed ID: 11850896
    [Abstract] [Full Text] [Related]

  • 13. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
    Boustanshenas M, Bakhshi B, Ghorbani M.
    J Appl Microbiol; 2013 Feb 08; 114(2):509-15. PubMed ID: 23082752
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.
    Bull Pan Am Health Organ; 1995 Dec 08; 29(4):312-21. PubMed ID: 8605522
    [Abstract] [Full Text] [Related]

  • 15. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T.
    Rev Alerg; 1993 Dec 08; 40(4):91-4. PubMed ID: 8143024
    [Abstract] [Full Text] [Related]

  • 16. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M, Cheong TG, Kurunathan S, Chandrika M, Ledon T, Fando R, Lalitha P, Zainuddin ZF, Ravichandran M.
    Microb Pathog; 2010 Nov 08; 49(5):211-6. PubMed ID: 20558271
    [Abstract] [Full Text] [Related]

  • 17. The expression of biologically active cholera toxin in Escherichia coli.
    Broadbent DA, Gennaro ML, Greenaway PJ.
    Dev Biol Stand; 1983 Nov 08; 53():85-8. PubMed ID: 6307786
    [Abstract] [Full Text] [Related]

  • 18. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation.
    Ravichandran M, Ali SA, Rashid NH, Kurunathan S, Yean CY, Ting LC, Bakar AS, Lalitha P, Zainuddin ZF.
    Vaccine; 2006 May 01; 24(18):3750-61. PubMed ID: 16102875
    [Abstract] [Full Text] [Related]

  • 19. [Expression of S.sonnei form I antigen gene and V.cholerae toxin B subunit gene in S.flexneri 2a strain and investigation of their immunoprotective response in mice].
    Qian F, Rui X, Su G, Huang C.
    Yi Chuan Xue Bao; 1996 May 01; 23(4):322-8. PubMed ID: 8950856
    [Abstract] [Full Text] [Related]

  • 20. Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation.
    Borde A, Larsson A, Holmgren J, Nygren E.
    Eur J Pharm Biopharm; 2011 Nov 01; 79(3):508-18. PubMed ID: 21757004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.